Stamulumab
Stamulumab
Stamulumab (pronounced stam-yoo-luh-mab) is a monoclonal antibody designed for the treatment of muscular dystrophy. It was developed by Wyeth, a pharmaceutical company now owned by Pfizer.
Etymology
The name "Stamulumab" is derived from the Latin word "stamus" meaning "we stand" and "lumab" which is a common suffix for monoclonal antibodies.
Function
Stamulumab works by binding to myostatin, a protein that inhibits muscle growth. By blocking the action of myostatin, Stamulumab allows for increased muscle growth and strength.
Clinical Trials
Stamulumab has undergone Phase I and Phase II clinical trials. The results showed potential benefits for patients with muscular dystrophy, but further research is needed to confirm these findings.
Related Terms
See Also
External links
- Medical encyclopedia article on Stamulumab
- Wikipedia's article - Stamulumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski